trending Market Intelligence /marketintelligence/en/news-insights/trending/dfkhmfhpwu_vqcma1si4zg2 content esgSubNav
In This List

ASCO conference: Celgene provides updated data for blood cancer combo study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ASCO conference: Celgene provides updated data for blood cancer combo study

Celgene Corp. presented detailed data from a late-stage study investigating the combination of its medicine Revlimid with Roche Holding AG's Rituxan to treat a type of blood cancer.

The study, known as Relevance, was determining whether a combination of Revlimid and Rituxan was better than the current standard of care — Rituxan plus chemotherapy — in patients with previously untreated follicular lymphoma. As previously reported, the study did not meet its objective.

Celgene noted that the combination offered numerically similar efficacy results when compared to the current standard of care. Specifically, 48% of the patients on the Revlimid-Rituxan combination arm had no detectable cancer remaining after treatment at a 120-week follow-up compared to 53% of those receiving the standard of care.

Furthermore, the Revlimid-Rituxan combination helped contain the disease for 77% of the patients at a three-year follow-up, a measure known as progression-free survival. This would compare to 78% for those receiving Rituxan plus chemotherapy.

The company continues to study the combination in a trial known as Augment in patients with indolent lymphomas.

The 2018 American Society of Clinical Oncology meeting is expected to bring together more than 32,000 professionals from all over the world, with more than 2,500 study abstracts to be presented on-site and an additional 3,350 abstracts to be published online.